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ABSTRACT (Maximum 200 Words)
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS), i.e. lobular neoplasia (LN), are lesions of significance in terms of risk to the patient in the development of invasive carcinoma.
A correlation between the lobular histological type and inactivation of E-cadherin, a cell adhesion protein, has been reported.
As well, mutations in CDHI have been reported in invasive lobular carcinoma (ILC) and LCIS with adjacent ILC.
Our study proposes to investigate LN lesions, lacking any adjacent invasive carcinoma, for alterations in and expression of known and novel genes/proteins with the goal of characterizing a molecular genetic profile.
We have accrued 36 cases containing ALH/LCIS without adjacent invasive carcinoma.
Previous studies have found negative Ecadherin, beta-and alpha-catenin protein expression in these lesions.
Moreover, LCIS but not ALH cases were characterized by mutations and LOH at 16q was found to be an infrequent event.
Recent studies have also demonstraed cytoplasmic (rather than membrane) localization of p120-catenin in LN lesions.
As a mechanism for the inactivation of Ecadherin has yet to be elucidated in LN, we have used CGH microarrays to study 12 ALH and 14 LCIS lesions.
Following validation by Real Time PCR it will be possible to describe events occurring at the earliest stages of breast cancer.
Introduction Lobular neoplasia (LN) is a histological classification that includes atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS). These breast lesions are of epithelial origin and histologically show a proliferative gradation from ALH to LCIS. Although a finding of LN is usually incidental during breast tissue biopsy, the relative risk to the patient in the development of invasive breast cancer is noteworthy. In fact, a number of epidemiological studies have reported that ALH and LCIS lesions are high-risk indicators, conferring a respective 4 to 5 and 8 to 10 fold increase risk.1 3 Previous work by our group (reported in Annual Summary Reports for 2002-2003 and 2003-2004) and others, investigated these lesions with respect to E-cadherin, a cell adhesion protein found on the membrane of epithelial cells. 4 -1 6 Membrane E-cadherin protein expression, as well as expression of beta-and alpha-catenin, have been found to be completely and simultaneously lost in ALH, LCIS and invasive lobular carcinoma (ILC). In studies investigating ILC, the loss of expression has been explained by the acquisition of inactivating mutations in the E-cadherin gene (CDH1) coupled with loss of heterozygosity (LOH) at the chromosome locus of 16q (where CDH1 is located). However our study, specifically investigating ALH and LCIS lesions not in the presence of an invasive cancer, was unable to provide an explanation for the loss of E-cadherin protein expression in the context of CDH1 mutation and LOH at 16q.
Body
Please note that the writing of this report is based on the revised SOW submitted to USARMC early in 2005. A copy of this SOW has been appended to the report (Appendix 1).
Our studies of lobular neoplastic lesions have used the cases collected through the Mount Sinai Hospital Pathology Department. These cases were accrued with the assistance of Dr. Frances O'Malley and as of April 2005 case accrual has concluded (Task 2a). All cases in the collection are formalin-fixed, paraffin-embedded archived breast tumor blocks containing lobular neoplastic lesions lacking adjacent invasive carcinoma and, at completion, the collection includes 36 cases of ALH/LCIS.
In previous work, we established that although LCIS lesions are characterized by mutation it is likely that a mechanism other than mutation/LOH is the cause of the loss of Ecadherin protein expression in early lobular neoplastic lesions, especially in cases containing ALH. Therefore it is necessary to evaluate other mechanisms by which CDH1 may be inactivated. To this end, evaluation of methylation of the CDH1 promoter had been proposed (Task 3c, 3d). However, optimization of the methylation-specific PCR (MSP) technique17 was unsuccessful. MSP requires a large quantity of sodium bisulfite modified DNA which was unable to be obtained from our cases of ALH/LCIS. The MethyLight technique 18, 19 was also attempted because it had greater sensitivity and required less DNA template. However despite these attributes, efficient and reproducible amplification of the target promoter area was unable to be optimized, again attributed to the DNA template. Given that there are no other template options for the cases in our collection (i.e. DNA from frozen tissue), this study has been discontinued.
The optimized protocol for p120-catenin immunohistochemistry (IHC) and staining of the ALH/LCIS cases with this antibody was previously reported to be complete (Task 5a-c, Annual Report 2003 Report -2004 . Subsequently, the scoring system has been developed to evaluate the IHC for p120-catenin (Task 5d). The scoring system created assesses not only a lack of circumferential membrane staining but also the cytoplasmic localization of the protein. All LCIS lesions showed no membrane but diffuse cytoplasmic staining, as well as 10 of 11 ALH lesions, with only one case (A7) showing positive circumferential membrane staining. Together with the previously reported IHC results for E-cadherin, beta-catenin and alpha-catenin, we can conclude that without the presence of an invasive lesion the expression of the entire E-cadherin complex at the cell membrane is altered in both ALH and LCIS lesions.
Understanding the picture outside of the E-cadherin complex could be key to discerning what is altered in these early breast lesions. For this we had proposed using comparative genomic hybridization (CGH) microarrays (Task 4) to determine what other known or novel genes are altered at the lobular neoplastic stage. The collection of cases able to be studied by array-CGH (aCGH) includes 17 ALH and 15 LCIS lesions. For each lesion, four to six 8uM sections were microdissected by either laser capture microdissection or stereomicroscope-based needle dissection and DNA was extracted (Task 4a). The DNA was labeled with Cy3 and aCGH successfully performed on 12 ALH and 14 LCIS (using a female genomic DNA labeled with Cy5 as reference) (Task 4b). Each array was scanned (Applied Precision Arrayworx CCD scanner) and then the array images were loaded into the analysis software (Applied Precision Softworx) and overlaid with the spot grid. The raw data was exported from this program and subsequently visualized using SeeGH software.
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All arrays were analyzed using SeeGH and subsequently statistically analyzed 21 to determine if the regions found were significant (Task 4c). The statistical analysis revealed regions of alteration also found by SeeGH. In general, a greater number of alterations were found in the ALH lesions compared to the LCIS. Regions specific to ALH or LCIS are identifiable, however, there appear to be no regions that are common to the paired lesions (cases containing both ALH and LCIS). Real Time PCR is currently being optimized to validate some areas of amplification found by aCGH (Task 4d). Primer/probe sets specific to genes at Ipl 1.2, 1Op 15.2, and 20q 13.13 are being assessed.
Training Experiences (2004 Experiences ( -2005 Teresa Mastracci is receiving her research training in the laboratory of Dr. Irene Andrulis at the Fred A. Litwin Centre for Cancer Genetics in the Samuel Lunenfeld Research Institute (SLRI) of Mount Sinai Hospital. As with any laboratory, Dr. Andrulis' lab has had turnover in the last year with the graduation of students and the acquisition of new associates. However, the laboratory continues to provide a rich research environment with 1 research associate, 2 postdoctoral fellows, 3 research technicians, 2 M.Sc. and 5 Ph.D. students. Moreover, the schedule of weekly lab meetings as well as monthly meetings with other groups in the Centre for Cancer Genetics has been maintained.
The Department of Laboratory Medicine and Pathobiology at the University of Toronto, to which Teresa is affiliated, requires the completion of 5 courses for students in the PhD program; a requirement that was fulfilled this year. Furthermore, the Department has maintained regular weekly Research Seminars which feature distinguished scientists from outside and within Toronto as well as weekly Departmental Student Seminars which give students the opportunity to present their research and receive input from the staff about their studies.
Both the University and SLRI hold yearly retreats where students and faculty present their work in a relaxed environment, facilitating discussion between laboratory groups. Teresa has presented at both of these events this year.
The Student Supervisory Committee monitors a student's progress regularly during his/her graduate career. It consists of the supervisor plus at least two other members of the Department, one of who should be from an area that is outside of the supervisor's immediate area of expertise. Committee meetings for Teresa have been consistently held every six months.
Dr. Andrulis' laboratory has also recently become involved in a weekly Molecular Medicine journal club held at the Hospital for Sick Children in Toronto. In addition, Teresa was invited to attend and present at the weekly Work In Progress Seminar Series hosted by Dr. Tak Mak at the Breast Cancer Research Institute at Princess Margaret Hospital. In the past, Teresa also has had the opportunity to attend and present at international conferences and this year has been invited to give a platform presentation at the Era of Hope DOD BCRP Meeting.
Key Accomplishments (2004) (2005) "* Case accrual has been completed. The collection includes 36 cases of ALH/LCIS. "* Optimization of a methylation specific PCR protocol was unsuccessful due to the limited amount of DNA able to be obtained from each ALH/LCIS case and therefore this study has been discontinued.
" Twelve ALH and 14 LCIS lesions were successfully arrayed using the tiling BAC array generated in the laboratory of Dr. Wan Lam. 22 The results from these microarrays have been analyzed and regions specific to only ALH or LCIS cases have been identified. Real Time PCR is currently being optimized to validate some of these areas including I p 1.2, 1Op 1 Conclusions ALH and LCIS lesions, without the presence of adjacent invasive disease, both show loss of the entire E-cadherin protein complex. Although we have shown that LCIS lesions are characterized by mutations, the genetic hits of mutation and loss of heterozygosity cannot explain this loss of E-cadherin protein expression (as well as the related loss of beta-, alpha-and p120-catenin). With the use of CGH microarray, we have found that ALH lesions appear to have a greater number of genetic alterations compared to LCIS lesions. Although many of these alterations are common to both neoplastic lesions, there appear to be regions that are specific to only ALH or LCIS. As the specific areas of amplification and deletion are currently being validated we cannot speculate yet as to the specific genetic events occurring in these lesions. However once complete, this study will define a genetic signature for lobular neoplasia that clearly describes events occurring at the earliest stages of breast cancer. Breast cancer is one of the most prevalent human cancers and a leading cause of death among women. Lobular neoplasia is a classification of breast lesions that includes atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS). Both ALH and LCIS are premalignant lesions that are impalpable and mammographically silent. Though these lesions are only found incidentally during breast biopsy, ALH/LCIS lesions are significant in terms of implication of risk to the patient in the development of invasive carcinoma. A strong correlation between the lobular histological subtype and inactivation of E-cadherin, a protein involved in cell adhesion, has been reported. As well, mutations in the E-cadherin gene (CDH1) have been reported in invasive lobular carcinoma (ILC) and LCIS with adjacent ILC. We have been investigating lobular neoplastic lesions, lacking any adjacent invasive carcinoma, for alterations in and expression of known and novel genes/proteins with the goal of characterizing a molecular genetic profile for lobular neoplasia.
We have obtained 21 archived cases of which there are 13 ALH lesions and 13 LCIS lesions all without adjacent invasive carcinoma. E-cadherin, beta-, alpha-, and pl20-catenin protein expression were assessed by immunohistochemistry (IHC). Sequence alterations in CDH1 were identified using Single Strand Conformation Polymorphism (SSCP)/manual sequencing and PCR-based loss of heterozygosity (LOH) analysis was carried out for the 16q locus. Following the characterization of the Ecadherin complex, array-CGH was used to determine gene copy number alterations in these cases.
By IHC, we have found negative E-cadherin (23/24), beta-catenin (23/24), and alpha-catenin (21/23) protein expression in these lesions. Cytoplasmic (rather than membrane) localization of p120-catenin was observed in 20 of 21 lesions. LCIS cases were characterized by mutations, however ALH cases were not. LOH at 16q was found to be an infrequent event. Array-CGH has been carried out on 11 LCIS and 9 ALH lesions and the data is currently being analyzed to determine the molecular genetic profiles.
Loss of the E-cadherin adhesion complex is an early event in lobular neoplasia affecting ALH as well as LCIS and occurs prior to progression to invasive disease. However, loss of E-cadherin protein expression is accompanied by DNA alterations in LCIS but not in ALH. Cases lacking both protein expression and gene alterations suggest that another mechanism is involved, possibly as early as at the hyperplastic stage, causing the silencing of the E-cadherin complex. Moreover, the array-CGH study may allow us to characterize a molecular genetic profile for lobular neoplasia, identifying events that mark the earliest stages in the development of cancer. This advance will significantly expand our ability to design strategies for the prevention of invasive carcinoma and could identify targets for therapeutic treatment. Tumor development from an early lesion through to invasive disease is not a clearly defined progression in the breast. Studies of invasive lobular carcinoma have reported mutations, loss of heterozygosity (LOH) and loss of protein expression in epithelial (E)-cadherin, a protein involved in cell adhesion. Our study examines in situ lobular neoplastic lesions without concurrent invasive carcinoma for E-cadherin gene alterations and protein expression, beta-catenin, alpha-catenin and p120-catenin protein expression, and LOH at the chromosome 16q locus, with the goal of determining the events occurring at the stage of lobular neoplasia. In all, 13 atypical lobular hyperplasia lesions and 13 lobular carcinoma in situ lesions from archived cases were examined. E-cadherin sequence alterations were evaluated using single strand conformation polymorphism and DNA sequencing, and PCR-based LOH analysis was carried out for the 16q locus. Using immunohistochemistry, we assessed protein expression. A total of 23 of 24 lesions evaluated by immunohistochemistry were negative for both E-cadherin and beta-catenin protein expression, and 21 of 23 lesions were negative for alpha-catenin. Cytoplasmic (rather than membrane) localization of p120-catenin was observed in 20 of 21 cases. Lobular carcinoma in situ cases were characterized by mutations; however, atypical lobular hyperplasia cases were not. LOH at 16q was an infrequent event. From our study, we conclude that an altered E-cadherin adhesion complex is an early event affecting atypical lobular hyperplasia as well as lobular carcinoma in situ and occurs prior to progression to invasive disease. However, the loss of protein expression is accompanied by E-cadherin DNA alterations in lobular carcinoma in situ but not in atypical lobular hyperplasia. These cases lacking both protein expression and gene alterations suggest that another mechanism is involved, possibly as early as at the hyperplastic stage, causing silencing of the E-cadherin complex.
Modern Pathology advance online publication, 14 January 2005; doi: 10.1038/modpathol.3800362
Keywords: atypical lobular hyperplasia; breast cancer; E-cadherin; lobular carcinoma in situ;, lobular neoplasia Tumor development from an early lesion through to carcinoma.' Our study investigates in situ lobular invasive disease is not a clearly defined progression neoplastic lesions that have not progressed to in the breast. For invasive breast carcinomas of the invasive disease with the goal of determining the lobular histological subtype there is increasing molecular genetic events occurring at the stage of evidence that in situ lobular neoplastic lesions are lobular neoplasia. Discovering the specific events not only indicators of increased risk but may also that mark the transition from an early lobular act as precursors in the progression to invasive neoplastic lesion to an invasive tumor is necessary to both support and subsequently understand this breast cancer progression. morphic and discohesive. The lesion is often multicentric and bilateral, and greater than 50% of events occurring specifically at the hyperplastic the acini in the affected terminal duct lobular unit and in situ stages, it is necessary to examine cases are distended by the cellular proliferation. The cells where the neoplastic lesion is not contaminated by that define atypical lobular hyperplasia are similar an invasive lesion. Cases containing atypical lobular to those that characterize lobular carcinoma in situ, hyperplasia and lobular carcinoma in situ without however, the cellular proliferation does not cornadjacent invasive carcinomas are known to occur in pletely occlude the lumen, and less than 50% of the only 0.5-3.8% of breast cases that are otherwise acini in the affected terminal duct lobular unit benign."' 9 These lesions have rarely been studied at exhibit distension. 2 Both lobular neoplastic lesions the molecular level. We have accrued a collection of are found incidentally during breast tissue biopsy cases fitting these criteria, making it possible to due to their inability to be detected by palpation or determine protein expression and gene alterations mammography.
occurring at the stage of lobular neoplasia. Histologically, there is a proliferative gradation from lobular hyperplasia to in situ carcinoma, which is also reflected in the relative risk to the patient in the development of invasive disease. A number of Materials and methods epidemiological studies have reported that lobular Tissue Accrual neoplastic lesions are high-risk indicators.
3 -` A finding of atypical lobular hyperplasia has been
The study population consisted of 21 formalinreported to imply a four-to five-fold increased risk fixed, paraffin-embedded, archived cases accrued of subsequent carcinoma in either breast, and a through the Mount Sinai Hospital Pathology Departfinding of lobular carcinoma in situ implies an eightment (Toronto, ON, Canada). The cases were accesto ten-fold increased risk to the patient.
sioned from 1988 to 2003. The study pathologist In sporadic breast cancers, histological type has (FOM) reviewed each neoplastic lesion from hemabeen correlated with expression of the cell adhesion toxylin and eosin (H&E)-stained sections. Previously protein epithelial (E)-cadherin, the cadherin subdescribed histological characteristics 20 were used to type expressed in epithelial cells. Proteins that classify the lobular lesions. The collection included complex with E-cadherin at the cell membrane 13 atypical lobular hyperplasia lesions (A1-A13) include beta-, gamma-, alpha-and p120-catenin. and 13 lobular carcinoma in situ lesions (L1-L12) Reduced expression of E-cadherin has been reported lacking adjacent invasive carcinoma. Four of these in invasive ductal carcinoma whereas lobular cases contained both hyperplasia and in situ lesions carcinoma in situ and invasive lobular carcinoma (A2/L1, A3/L3, A4/L5, A1l/L12). More specifically, show complete loss of the protein.'-'" A report on case A2/L1 was also characterized by multifocal invasive lobular carcinomas with adjacent lobular lobular carcinoma in situ (L1-1, L1-2) and these carcinoma in situ demonstrated not only loss of Ein situ lesions were housed in separate blocks. cadherin expression but also the simultaneous loss Two cases of interest, supplementary to our of beta-, gamma-and alpha-catenin protein exprescollection, were also included in all analyses. Case sion." More recently, Sarrio et aP 7 demonstrated A14/L13 contained atypical lobular hyperplasia and that the loss of E-cadherin along with the cytoplaslobular carcinoma in situ lesions as well as a focus mic localization of p120-catenin characterizes lobuof invasive lobular carcinoma in a separate block; lar breast cancers and suggested that p120-catenin the lobular neoplastic lesions were analyzed. Moreplays a role in mediating the oncogenic effects of Eover, case P1 contained a lesion of low-grade ductal cadherin loss in these cancers. Unquestionably there carcinoma in situ that was used as a control for the is evidence that an altered E-cadherin adhesion immunohistochemistry analyses. All cases were complex is characteristic of invasive lobular carcicoded to prevent bias and maintain confidentiality. noma and lobular carcinoma in situ with adjacent
To determine the robustness of the histological invasive lobular carcinoma, classification of the lesions, all cases were reviewed In light of these findings, several studies have independently by a second pathologist (ALB) investigated the E-cadherin gene, CDH1, for alterablinded to the results of the molecular analyses. tions in lobular carcinomas. Mutations have been There were discrepancies in two cases. Both cases detected in invasive lobular carcinoma and lobular had been called lobular carcinoma in situ by the first carcinoma in situ with adjacent invasive, 6,11-1 and pathologist (FOM) and 'atypical lobular hyperplasia the loss of chromosome 16q was detected in solitary with duct involvement by cells of atypical lobular in situ and synchronous in situAnvasive lesions."' 8 hyperplasia' by the second pathologist (ALB). A These investigations of lobular carcinoma and Econsensus diagnosis of lobular carcinoma in situ cadherin have provided some evidence that in situ was reached for both cases by the pathologists lobular carcinoma may be not only a risk indicator following rereview at a multiheaded microscope. but also a precursor lesion to invasive carcinoma.
Ultimately, the pathology review confirmed that our To date, most molecular genetic studies of lobular collection contained 13 atypical lobular hyperplasia carcinoma in situ have focused on lesions with and 13 lobular carcinoma in situ lesions without adjacent invasive carcinoma. However, to study adjacent invasive carcinoma.
Microdissection, DNA Extraction and DNA Amplification
From each case, serial sections (8 pm) were cut from the block containing the lesion of interest and mounted on glass slides. Following deparaffinization, the lesion was removed from the section using either a stereomicroscope-based microdissection technique 2 1 or laser-capture microdissection (PixCell II, Arcturus, CA, USA). The microdissection technique used was determined by the size of the lesion. The majority of the in situ lesions (LI-1, Li-2, L2, L4, L6-L11) were microdissected using the stereomicroscope-based technique due to large lesion area. However, all hyperplasia lesions (Al-A14) were small in size and required laser-capture microdissection in order to accurately remove the j lesion from the surrounding tissue. Cases L3, L5, L12 and L13 were also microdissected by lasercapture microdissection because they contained both neoplastic lesions in close proximity in the same section. Figure 1 depicts a case containing atypical lobular hyperplasia from our collection and demonstrates the lesion before and after lasercapture microdissection, as well as the degree of cellularity of a typical atypical lobular hyperplasia lesion for our collection. Whether by stereomicroscope or laser-capture, the use of a microdissection and DNA was extracted using the QiaAMP DNA Mini Kit (Qiagen, Canada).
As neoplastic lesions are small in size, the amount 0.05% bromophenol blue, 0.05% xylene cyanol FF) Exon-specific PCR conditions were optimized for all was added to the SSCP reactions, which were primer pairs (exons 1-3, 6 -1 6 6; exons 4-51).
subsequently heat denatured and subjected to Amplification was performed in a volume of 30 pl electrophoresis on an 8% nondenaturing polyacrycontaining 10 l1 of DOP PCR product template, 1 x lamide gel (including 10% glycerol). Two gels were High Fidelity PCR Buffer, 2 mM MgSO 4 Following sectioning for microdissection, 4 yi the SSCP reaction was repeated for that case using sections were cut for each formalin-fixed, paraffin-5,pl of microdissected DNA template that had not embedded block, and mounted on glass slides. Each been subjected to DOP PCR amplification (PCR/ section was deparaffinized in xylene and rehydrated SSCP conditions as previously stated). If the through graded alcohols to distilled water. Followabnormal banding pattern could be duplicated in ing heat antigen retrieval, the primary antibodies to this second independent SSCP experiment, then the E-cadherin (HECD-1, Monoclonal Mouse anti-Ealteration was characterized using manual DNA cadherin 2nd Gen Predilute Antibody, Zymed sequencing.
Laboratories Inc., USA), beta-catenin (Monoclonal To characterize CDH1 alterations, aberrantly miMouse anti-beta-catenin, 1:6000 dilution, Transducgrating bands were excised from the dried SSCP gel tion Laboratories, USA), alpha-catenin (NCL-A-CAT, and DNA was extracted using a serial freeze-thaw Monoclonal Mouse anti-alpha-catenin, 1:50 dilutechnique. In all, 5 pl of the extracted DNA was used tion, Novocastra Laboratories Ltd, UK) or p120-as template in an exon-specific PCR reaction using catenin (p120-ctn (15D2), 1:50 dilution, Santa Cruz the conditions previously outlined. The Thermo Biotechnology, Inc., USA) were applied. The
Sequenase Radiolabelled Terminator Cycle SequenUltra Streptavidin Detection System (Signet cing Kit (Amersham Pharmacia Biotech, Canada) Laboratories Inc., USA) was used as per the was used to manually sequence the DNA, according manufacturer's instructions for all antibodies to the manufacturer's instructions. Results were except alpha-catenin, which required the ELITE obtained following autoradiography. Alterations that Detection System (Vector Laboratories (Canada) Inc., were found were confirmed by repeating the sequenCanada). Each section was developed with the cing using microdissected DNA (not previously chromogen diaminobenzidene and sections were preamplified by DOP PCR) as template from both counterstained in hematoxylin. the forward and reverse direction for each exon.
Some cases have insufficient material to carry out immunohistochemistry due to sectioning order. Sections were cut from each case for immunohistochemistry analyses only after sectioning was Loss of Heterozygosity (LOH) complete for microdissection. In some cases, the LOH was evaluated for the E-cadherin gene located lesion of interest was no longer present in the on chromosome 16q. Five microsatellite markers, immunohistochemistry section and therefore no located at chromosome locus 16q21-16q22.1, were result could be obtained. used (D16S421, D16S496, D16S503, D16S3095, Immunohistochemical staining was reviewed and D16S752). Microdissected DNA from each lesion scored by the study pathologist. To evaluate the (not preamplified by DOP PCR), paired with DNA immunohistochemistry for E-cadherin, beta-catenin from an adjacent area of normal tissue, was used as and alpha-catenin protein expression, a positive template to examine LOH.
stain was determined to be complete circumferential PCR amplification was performed in a volume of membrane staining of the lobular neoplastic cells. 30pl containing 5 p1 of microdissected DNA temThe case of low-grade ductal carcinoma in situ (P1) plate, 1 x High Fidelity PCR Buffer, 2 mM MgSO 4 , was used as a positive control for E-cadherin, beta-0.2 mM of each dNTP, 0.3 pM of forward and reverse catenin and alpha-catenin staining as it expressed primers, 1 U of PLATINUM Taq DNA polymerase these proteins at the membrane. Evaluation of the High Fidelity (GIBCO BRL, Life Technologies, immunohistochemistry for p120-catenin required Canada). and 0.1 tiCi of [ 3 3 P~dATP (Perkin-Elmer, assessment of the circumferential membrane stain-USA). Following an initial denaturation step at 94°C ing as well as the cytoplasmic staining pattern. A for 3 mi, 40 cycles of 94°C for 15 a, 54°C (D16S503) formalin-fixed, paraffin-embedded breast cancer cell or 57°C (D16s421, D16S496, D16S752, D16S3095) line (MCF7) was used as the positive control for the for 15 s, and 72°C for 20 s were performed. A stop p120-catenin immunohistochemistry as it contained solution (as previously described) was added and membrane localized p120-catenin. each reaction was subsequently heat denatured. and subjected to electrophoresis on a 7% denaturing formamide gel, which was run at 80W for 3 h.
Results
Results were obtained following autoradiography.
CDHI Mutation Analysis Multiple independent observers evaluated each marker, scoring each case as 'LOH', 'no LOH', or Using the manual DNA sequencing technique, 16 'uninformative'. To evaluate each marker, LOH was polymorphisms (data not shown) and 15 mutations defined as a relative decrease in band intensity (Table 1) were characterized. Three mutations (cases greater than 50%. For each case, a minimum of three A12, L4, L8) were deletions causing a frameshift and of the five markers with observed LOH was required a premature stop codon. In all, 11 sequence alterafor an overall classification of LOH.
tions were classified as missense mutations (cases Table 1 (-) , negative membrane staining; (+), positive membrane staining; NR = no result due to insufficient material; cyto diffuse cytoplasmic staining. 'All cases contained adjacent normal breast acini that served as the internal positive control for the immunohistochemical analyses. bCase A14/L13 contained atypical lobular hyperplasia and lobular carcinoma in situ lesions as well as a focus of invasive lobular carcinoma in a separate block. The lobular neoplastic lesions were analyzed. cCase P1 contained a lesion of low-grade ductal carcinoma in situ and was used as a positive control for the E-cadherin, beta-catenin and alphacatenin immunohistochemistry experiments as it contains no lobular neoplasia.
LU-1, L1-2, L2, L3, L5, L6, L7, L9, L10, L1i, L12). homology-based tool. Of the 11 missense mutations, The mutations were found in exons 3, 6, 7, 9, 10, 11, three were predicted by SIFT not to be tolerated 12, 13 and 15. With the exception of the missense amino-acid substitutions (case L5, L9, L10). mutation found in case Li-1 (previously reported by Case A14/L13, noted as containing adjacent Rieger-Christ et a]"), all alterations found in this atypical lobular hyperplasia and lobular carcinoma study are novel, in situ lesions as well as invasive lobular carcinoma Four cases (A2/L1, A3/L3, A4/L5, All/L12) in a separate block, was found to contain a nonsense contained both atypical lobular hyperplasia and mutation in exon 11. As observed in the four cases lobular carcinoma in situ lesions. Each of these containing both lobular neoplastic lesions, the cases of lobular carcinoma in situ contained a sequence alteration is present in the in situ sequence alteration that was not detected in the component but not in the hyperplasia. Figure 2 adjacent hyperplastic lesions. In addition to conshows the mutation found in L13 and the corretaining both types of lesions, case A2/L1 contained, sponding sequence from the adjacent hyperplasia in separate blocks, two lobular carcinoma in situ (A14) lacking the alteration.
lesions (Li-1, L1-2). These in situ lesions were microdissected individually and each was found to harbor different missense mutations.
Loss of Heterozygosity
In order to predict if the missense mutations found in our cases of lobular carcinoma in situ LOH was evaluated with five microsatellite markers would have a phenotypic effect we used SIFT and each case was evaluated paired with its (http://blocks.fhcrc.org/sift/SIFT.html), a sequence corresponding normal for each marker (Table 1) .
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We observed 80-100% agreement between observers out LOH analysis (A3, A6, L9). Of the remaining and questionable cases were repeated and reevalucases, three were found to have LOH (A10, L1-2, L7) ated. Three cases had insufficient material to carry and 20 showed no LOH ( Figure 2) . 
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A-2 L-2 N-2 tic cases, with negative E-cadherin and beta-catenin protein expression. For alpha-catenin, 10 of 11 lobular carcinoma in situ and 11 of 12 atypical lobular hyperplasia lesions were scored as negative, and two cases (A7, L8) were positive. The case of low-grade ductal carcinoma in situ (P1) stained positive for E-cadherin, beta-catenin and alpha-W'0 no P""catenin.
Moreover, all cases contained adjacent normal epithelium that served as an internal a +positive control and in all cases showed complete circumferential membrane staining (Figure 4 ). lesions is substantial when considering the ambig- 1Ž 'I 5'
,.
,sr
'V ¶.7S *#i uous understanding of the molecular genetic events istic to the lobular neoplastic cells in all but one occurring at these early stages.
case. We postulate that this one exceptional case A number of studies have shown that E-cadherin (A7), with membrane localization of all proteins of is completely inactivated in invasive lobular carcithe E-cadherin complex, has not yet undergone the noma. Definitively, from our study of neoplastic molecular genetic events that cause inactivation of lesions, we can conclude that lobular lesions, the E-cadherin complex. Irrespective of case A7, the whether hyperplasia or carcinoma in situ, lack Eresults of our immunohistochemical analyses decadherin membrane staining. These immunohistomonstrate that without the presence of an invasive chemistry results support the previously reported lesion the expression of the entire E-cadherin correlation between protein inactivation and histocomplex at the cell membrane is altered in both logical type. Furthermore, the data indicate that this atypical lobular hyperplasia and lobular carcinoma correlation is not restricted to lobular carcinoma in situ lesions. in situ and invasive lobular carcinoma but can be The use of a whole genome amplification techniextended to atypical lobular hyperplasia as well.
que to increase the quantity of the DNA template In addition, a complete lack of beta-catenin and obtained from the lobular neoplastic lesions made it alpha-catenin protein expression as well as cytopossible to complete the screening of CDH1 for plasmic localization of pl20-catenin was charactersequence alterations. DOP PCR has been used previously in combination with SSCP and is adjacent invasive lesion, we suggest that the sensitive with respect to amplifying small quantities presence of an inactivating CDH1 mutation could of DNA. 23 According to us CDH1 mutation analysis be an event that distinguishes lobular carcinoma by DOP PCR-SSCP was reliable, as aberrantly in situ lesions that are precursors from those that are migrating bands found by using this technique not. could be duplicated by SSCP using microdissected
The frameshift mutations found in cases L4, L8 DNA, without prior amplification by DOP PCR, as and A12 are likely to have an effect on protein template.
function. The bioinformatics tool, SIFT, clarified to Only one (A12) of 13 atypical lobular hyperplasia some extent the functional significance of the lesions contained an alteration. On the other hand, missense mutations we detected. As only three every case of lobular carcinoma in situ analyzed has missense mutations were predicted to affect protein been found to harbor a sequence alteration (13/13) . function, it is likely that lobular carcinoma in situ To date, there have been no mutations reported in lesions found to harbor only missense mutations do cases of lobular carcinoma in situ that lacked not progress to invasive carcinoma. The presence of adjacent invasive carcinoma; somatic mutations a missense mutation could simply indicate an have only been found in invasive lobular carcinoma environment amenable to genetic alteration, as or lobular carcinoma in situ with adjacent invasive observed in case A2/L1 where adjacent in situ disease. Although the data do not allow us to lesions were found to harbor different missense speculate as to whether these in situ lesions are mutations. Moreover, since the loss of protein precursors to invasive carcinoma, we can conclude expression was not always associated with a that somatic alterations in CDH1 appear to occur sequence alteration, as in the cases containing predominantly at the in situ stage.
atypical lobular hyperplasia, we conclude that The study design, the sensitivity of the techniques mutation alone could not cause the lack of Eused and the high cellularity of the lesions of cadherin protein expression that we have observed. atypical lobular hyperplasia ruled out the possibiVery little is known about the molecular genetic lity of false-negative results with respect to CDH1 events occurring at the stage of atypical lobular mutation analysis. The microdissection techniques hyperplasia. To our knowledge, this study repreallowed for the isolation of each lesion from the sents the first investigation of alterations in Esurrounding tissue/adjacent lesions with no greater cadherin in atypical lobular hyperplasia. The overthan 15-20% contamination of non-neoplastic cells whelming absence of mutations in cases of atypical ( Figure 1 ). In addition, the lack of sequence alteralobular hyperplasia, coupled with a loss of Etions found in the hyperplasia cases was reproduced cadherin protein expression, suggests that in these in independent experiments using microdissected lesions, E-cadherin may be inactivated by means DNA (not previously preamplified by DOP PCR) other than the presence of mutation. To address this, from each atypical lobular hyperplasia lesion.
we evaluated these lesions for LOH. Altogether the trend that lobular carcinoma in situ LOH has been studied in lobular breast cancers but not atypical lobular hyperplasia cases carry and the chromosomal region of 16q, the location of alterations was prominent. Furthermore, this trend CDH1, 24 has been found to have a high degree of supports previous reports of a precursor role for LOH.
These previous studies have found in situ lesions as it demonstrates an increase in LOH to accompany mutations in cases of invasive genetic hits from hyperplasia to carcinoma in situ lobular carcinoma or lobular carcinoma in situ with characteristic of progression. adjacent invasive lobular carcinoma. However, in Moreover, in the cases that contained both lobular the present study, all cases of lobular carcinoma neoplastic lesions, the atypical lobular hyperplasia in situ were found to harbor mutations but LOH was and lobular carcinoma in situ were microdissected found in only two of these 13 cases. In both separately and in all cases the in situ component instances, LOH was detected in cases that harbored was found to harbor a sequence alteration, whereas missense mutations. The classic pattern of an hyperplasia did not. Even case A14/L13, noted in inactivating mutation coupled with LOH does not the pathology review as containing adjacent atypical appear to be characteristic of the lobular carcinoma lobular hyperplasia and lobular carcinoma in situ in situ lesions in our collection. lesions as well as invasive lobular carcinoma in a Methylation of the E-cadherin promoter has been separate block, was found to contain a mutation in reported in studies investigating invasive lobular the in situ stage but not hyperplasia. These cases carcinoma,' 6 breast carcinomas, 25 and breast cancer further substantiate our hypothesis that mutations cell lines that lack E-cadherin expression. 2 6 ', 7 In the are first detected at the in situ stage.
case of sporadic gastric carcinomas, promoter CDH1 sequence alterations reported to date in methylation has been described as a second hit studies investigating progression from lobular carcileading to inactivation of the E-cadherin gene. 28 We noma in situ to invasive lobular carcinoma have hypothesize that epigenetic mechanisms acting at been inactivating mutations. The nonsense mutation the hyperplastic stage could provide an explanation found in case A14/L13 was predicted to cause for the loss of E-cadherin that we have observed protein truncation. As this case (A14/L13) has an in both atypical lobular hyperplasia and lobular 
